Polycystic Ovary Syndrome
Conditions
Keywords
PCOS, oral contraceptive pill, polymorphisms
Brief summary
An association of the single nucleotide polymorphism (SNP) in the promoter gene that codify for 17b-HSD5 enzyme (71A\>G) with polycystic ovary syndrome (PCOS) and hyperandrogenemia has been suggested in previous studies. Given the role of 17b-HSD5 in androgenic metabolism producing testosterone from precursors, the investigators hypothesis is that women with PCOS and with the variant allele G have a poor response on hirsutism and on hormonal and metabolic variables after oral contraceptive pill (OCP) treatment for 6 months.
Interventions
ethinyl oestradiol 20ug plus gestodene 75ug during 6 cycles
Sponsors
Hospital de Clinicas de Porto Alegre
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Federal University of Rio Grande do Sul
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
15 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* hirsute women with polycystic ovary syndrome
Exclusion criteria
* Use of any drugs known to interfere with hormone levels for at least 3 months before the study * Women with type 2 diabetes, homa index \> 3.8, liver or renal disease or thyroid dysfunction * Other hyperandrogenic disorders than PCOS
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes at Ferriman- Gallwey score | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Changes at testosterone levels | 6 months |
| Changes in lipid profile | 6 months |
Outcome results
None listed